Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline
- PMID: 20804534
- DOI: 10.1111/j.1399-3062.2010.00561.x
Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline
Abstract
A total of 26 adults with hematologic malignancies and/or hematopoietic stem cell transplant were treated for respiratory syncytial virus (RSV) infection based on an institutional guideline. Thirteen patients received aerosolized ribavirin, and 13 received aerosolized ribavirin and intravenous palivizumab. Two deaths, not attributed to RSV infection, occurred within 90 days of diagnosis.
© 2010 John Wiley & Sons A/S.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
